@article {Dalton484, author = {Colin Dalton and Karl Verebely}, title = {HYPOTRIGLYCERIDEMIC ACTIVITY OF 5,5{\textquoteright}-DIPHENYL-2-THIOHYDANTOIN (DPTH)}, volume = {180}, number = {2}, pages = {484--491}, year = {1972}, publisher = {American Society for Pharmacology and Experimental Therapeutics}, abstract = {DPTH is a lipophilic compound which has similar pharmacological properties to 5,5{\textquoteright}-diphenylhydantoin. Oral administration of DPTH to rats caused a 60 to 80\% decrease in serum triglyceride concentration. Dose-response characteristics for lipid lowering over the range 0.5 to 200 mg/kg/day were determined after a two- and a nine-day dosage regimen. The dose-related decrease in serum triglyceride was accompanied by a dose-related increase in liver and thyroid weight and liver total lipid and phospholipid content. A hypotriglyceridemic effect was not seen with equivalent doses of 5,5{\textquoteright}-diphenylhydantoin or with the antithyroid substances, thiouracil, propylthiouracil, methylthiouracil and methimazole. In contrast to know antihyperlipidemic agents, DPTH had little lowering effect on serum cholesterol or phospholipid levels and at the higher doses studied DPTH had an elevating effect on serum cholesterol and phospholipid concentration. All the observed drug-induced effects were readily reversible upon withdrawal of the drug. It is suggested that DPTH lowers serum triglycerides by a mechanism unrelated to its antithyroid properties and differing from that of known antihyperlipidemic agents. {\textcopyright} 1972 by The Williams \& Wilkins Co.}, issn = {0022-3565}, URL = {https://jpet.aspetjournals.org/content/180/2/484}, eprint = {https://jpet.aspetjournals.org/content/180/2/484.full.pdf}, journal = {Journal of Pharmacology and Experimental Therapeutics} }